Pulse Biosciences, IncNASDAQ: PLSE

Pulse Biosciences Schedules Second Quarter 2026 Financial Results Conference Call for August 6, 2026

· Issued by Pulse Biosciences, Inc via Business Wire

Summary by 6ix AI

Pulse Biosciences, Inc., which is developing nanosecond pulsed field ablation technology (very short electrical pulses used to clear cells), will report business updates and financial results for the second quarter 2026 after market close on Thursday, August 6, 2026, and host a conference call beginning at 1:30pm PT / 4:30pm ET.

Key details

  • The call can be reached by dialing 1-800-715-9871 from the U.S. or 1-646-307-1963 internationally, using Conference ID 3486060.
  • A live and recorded webcast will be available on the Pulse Biosciences Investors website.

6ix AI wrote this summary from the release below and checked it against the release.

Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announced it will report business updates and financial results for the second quarter 2026 after market close on Thursday, August 6, 2026. Company management will host a corresponding conference call to discuss business updates beginning at 1:30pm PT / 4:30pm ET.

Investors interested in listening to the conference call may do so by dialing 1-800-715-9871 from the U.S. or 1-646-307-1963 internationally and providing Conference ID 3486060. A live and recorded webcast of the event will be available on the Pulse Biosciences Investors website at http://investors.pulsebiosciences.com/.

About Pulse Biosciences®

Pulse Biosciences is a novel bioelectric medicine company committed to health innovation that has the intention as well as potential to improve the quality of life for patients. The Company’s proprietary nPulse™ technology delivers nanosecond pulses of electrical energy to non-thermally clear cells while sparing adjacent non-cellular tissue as well as initiating regulated cell death. The Company is actively pursuing the development of its nPulse technology for use in the treatment of atrial fibrillation and in a select few other markets where it could have a profound positive impact on healthcare for both patients and providers.

Pulse Biosciences, nPulse, Vybrance, CellFX, Nano-Pulse Stimulation, NPS, nsPFA, CellFX nsPFA and the stylized logos are among the trademarks and/or registered trademarks of Pulse Biosciences, Inc. in the United States and other countries.

View original source (Business Wire)Pulse Biosciences, Inc on 6ix

Story so far

Earlier from Pulse Biosciences

Later from Pulse Biosciences

All Pulse Biosciences news releases